Relay Therapeutics, Inc. (RLAY)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Relay Therapeutics, Inc. reported revenue of $15.36M, up 53.4% from the prior year. The company ran a net loss, with a net margin of -1800.6%. It held $621.33M in total assets against $54.27M in total liabilities.
Key ratios (FY2025)
-1971.6%
Operating margin
-1800.6%
Net margin
-48.8%
Return on equity
+53.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M | $82.65M | — | — |
| Operating Income | -$302.74M | -$372.47M | -$373.00M | -$299.27M | -$364.70M | -$55.80M | -$84.05M | — |
| Net Income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$75.31M | — |
| EPS (Diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 | — | — |
| Total Assets | $621.33M | $871.30M | $843.98M | $1.10B | $1.01B | $799.83M | $393.07M | — |
| Total Liabilities | $54.27M | $93.50M | $91.98M | $149.55M | $110.64M | $36.54M | $35.73M | — |
| Shareholders' Equity | $567.06M | $777.79M | $752.00M | $950.22M | $897.81M | $763.29M | -$180.44M | -$110.93M |
| Cash & Equivalents | $84.02M | $124.29M | $143.74M | $151.79M | $280.12M | $447.65M | $41.95M | — |
| Operating Cash Flow | -$235.46M | -$249.11M | -$300.32M | -$229.49M | -$74.41M | -$102.49M | -$66.13M | — |
| Capital Expenditures | $410.0K | $2.02M | $4.13M | $9.06M | $3.47M | $1.93M | $8.00M | — |
| Shares Outstanding | 173.87M | 167.76M | 127.46M | 121.11M | 108.21M | 89.91M | 4.04M | — |